Summary
The development of fibrosis involves a multitude of events and molecules. Until now the majority of these molecules were found to be proteins or peptides. But recent data show significant involvement of the phospholipid lysophosphatidic acid (LPA) in the development of pulmonary, liver and renal fibrosis. The latest data on the role of LPA and the G-protein-coupled LPA 1 receptor in the development of renal fibrosis will be discussed. LPA 1 receptor-activation was found to be associated with increased vascular leakage and increased fibroblast recruitment in pulmonary fibrosis.
Furthermore, in renal fibrosis LPA 1 receptor-activation stimulates macrophage recruitment and connective tissue growth factor expression. The observations make this receptor an interesting alternative and new therapeutic target in fibrotic diseases.
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Renal fibrosis
Renal fibrosis is the principal process involved in the progression of chronic kidney disease (CKD) to end-stage renal disease (ESRD). As the incidence of ESRD continues to increase throughout the world, research to better understand the development of renal fibrosis has intensified [1, 2] . The development of renal fibrosis involves the progressive appearance of glomerulosclerosis, tubulointerstitial fibrosis (TIF) and changes in renal vasculature (loss of glomerular and peritubular capillaries). On a molecular level, fibrosis can be defined as excessive accumulation of extracellular matrix (ECM), such as collagens and fibronectins. The presence of TIF, compared to glomerular sclerosis, has been strongly correlated to evolution to ESRD [1, 3] . The first step in the development of TIF is inflammation associated with infiltration of macrophages, lymphocytes, and an increase in cytokine and chemokine seceretion (Figure 1 ). This inflammatory state induces a disequilibrium between apoptosis and proliferation of tubular cells, as well as accumulation of myofibroblasts.
Myofibroblasts
arise from epithelial mesenchymal transition, from proliferation/activation of the few resident fibroblasts or from infiltrated cells [1, 4] .
These myofibroblasts are the main cell type responsible for the secretion of the ECM.
As these events occur, the quantity of fibrotic tissue increases, causing a steady decline of renal function until eventually the kidney is no longer able to function and organ failure occurs. In the past a number of mediators of TIF have been identified including chemokines, cytokines and growth factors [5] . Among these, transforming growth factor (TGF) is thought to be the most fibrogenic, directly or indirectly, through the action of connective tissue growth factor (CTGF) [6] .
As most renal disease converts sooner or later to renal fibrosis, treatment aiming to slowdown, halt, or even better, reverse renal fibrosis will have an enormous
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impact in renal disease. The multitude of events and factors [5] involved in the development of renal fibrosis is reflected by the increasing number of experimental reports showing the potential anti-fibrotic effect of a number of strategies and compounds [2, 3] . However, the only currently clinically available drugs which have shown to slow down the progression towards ESRD are the inhibitors of the renin angiotensin system (RAS, [1] ). Unfortunately, even when treated with RAS inhibitors CKD continues to progress. Alternative molecules or therapies are thus necessary [2, 3] .
Phospholipids and Fibrosis
For the majority of organs and tissues the development of fibrosis involves a multitude of events and factors [7] , similar to what described above for the kidney.
Until now, the majority of these molecules were found to be proteins or peptides (profibrotic cytokines, chemokines, metalloproteinases etc… [7] ). But more recent data show significant involvement of phospholipids in wound healing [8] and in the development of fibrosis. These phospholipids include platelet activating factor (PAF), phosphatidyl choline and lysophosphatidic acid (LPA). Involvement of these three phospholipids in the development of fibrosis in various organs will be presented below, with a particular emphasis on LPA.
In vitro studies show PAF as an important actor in the development of renal tubulointerstitial fibrosis. PAF induces the production of the ECM-components collagen type I et IV and fibronectin by rat fibroblasts and tubular cells [9] . PAF also induces the production of the profibrotic cytokine TGF [10] . In vivo, genetic ablation or pharmacological blockade of the PAF receptor induces a significant decrease of folic acid-induced renal fibrosis in rodent models [11] . Furthermore, PAF is also inserm-00277902, version 1 -7 May 2008 involved in pulmonary fibrosis as administration of a PAF receptor antagonist attenuates bleomycin-induced pulmonary fibrosis [12] .
Other phospholipids are associated with the progression of pulmonary fibrosis.
Different studies describe an increase of phospholipid concentrations in the bronchoalveolar lavage fluid and in particular phosphatidylcholine (PC) in rabbits and rodents injected with bleomycin [13, 14] . The production of PC under these conditions might be beneficial as it was shown that dilinoleoylphosphatidylcholine in vitro and in vivo, induces a significant reduction in the expression of genes coding for ECM molecules and inflammatory mediators during bile duct ligation-induced liver fibrosis [15] .
LPA and fibrosis
LPA is a growth factor-like phospholipid known to regulate several cellular processes including cell motility, cell proliferation, cell survival, and cellular differentiation. LPA acts on specific G-protein coupled receptors (LPA 1 to LPA 5 ) [16] . Pharmacological tools to study the involvement of these different LPA receptors have been limited.
Currently, the most frequently used pharmacological agent is Ki16425 that has been shown to block LPA 1 -and LPA 3 -receptor subtypes both in vitro [17] and in vivo [18] .
Mice invalidated for the LPA receptor subtype 1, 2 and 3 are also available [19] [20] [21] .
Among the different bioactive phospholipids, lysophosphatidic acid (LPA) has been associated with the etiology of a growing number of disorders [22] . Furthermore, a number of studies suggest a role for LPA in the development of fibrosis (see the discussion below).
A number of muscular dystrophies are characterized by a progressive weakness and wasting of musculature, and by extensive fibrosis. It has been shown
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that LPA-treatment of cultured myoblasts induced significant expression of connective tissue growth factor (CTGF). CTGF subsequently induces collagen, fibronectin and integrin expression and induces dedifferentiation of these myoblasts [23] . This example is introducing the unambiguous link between LPA and CTGF; it has been shown that treatment of a variety of cell types with LPA induces reproducible and high level induction of CTGF [24] [25] [26] [27] [28] [29] [30] [31] [32] , although not necessarily in cells directly involved in the fibrotic process. CTGF is an important profibrotic cytokine, signaling down-stream and in parallel with TGF [33] . In this context CTGF expression by gingival epithelial cells, which are involved in the development of gingival fibromatosis, was found to be exacerbated by LPA treatment [34] .
LPA might also be associated with the progression of liver fibrosis. In vitro, LPA induces stellate cell and hepatocyte proliferation [35] . These activated cells are the main cell type responsible for the accumulation of ECM in the liver [36] . Furthermore, LPA plasma levels raise during CCl4-induced liver fibrosis in rodents, or in hepatitis C virus-induced liver fibrosis in human [37, 38] .
In addition it was recently shown, in an elegant study of Tager et al., that LPA is an important protagonist in the evolution of pulmonary fibrosis [39] . They first showed that LPA is detected in bronchoalveolar lavage fluid (BAL) and that its concentration is significantly increased in BAL of bleomycin-challenged mice. In the next step it was shown that genetic ablation (LPA 1 receptor knockout mice) or pharmacological [39] . Taken together these studies show that the LPA 1 receptor is a potential target in treatment of IPF. Unfortunately the role of CTGF in this pulmonary profibrotic action of LPA was not studied [39] .
Finally, we have recently identified a role for LPA and the LPA 1 receptor in the development of renal fibrosis which will be discussed in detail below after a more general state of the art of the knowledge of LPA and its role in renal pathophysiology.
LPA and renal pathophysioloy
In vivo: Only little information is available on the in vivo involvement of LPA in renal disease. LPA was shown to attenuate lesions induced by ischemia/reperfusion (I/R) in mice by inhibition of caspase-dependent apoptosis in tubular cells and reduced complement activation and neutrophil recruitment [40] . However, this protective role of LPA in I/R injury has been contested since the use of the LPA 3 receptor antagonist (VPC12249) induced a significant decrease in, and the use of a LPA analogue (OMPT) enhanced, the lesions induced by I/R [41] . Further studies are necessary to better define the role of LPA and its receptors in renal I/R injury. Other studies on patients with chronic renal failure have shown the presence of increased LPA concentrations in plasma [42, 43] . These studies showed that in 18 dialyzed patients with renal failure, plasma LPA levels were 3-fold higher in dialyzed patients than in controls (respectively 1,41  0,16 nmol/mL and 0,54  0,08 nmol/mL). These data suggest an abnormal LPA metabolism with renal failure, but the cause and
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consequences of elevated LPA levels under these conditions remains to be clarified [42] . As the renal expression of LPA receptors is relatively high (especially LPA 1/2 and LPA 3 receptors, [31, 41] ), this organ might be targeted by these high plasma LPA concentrations.
In vitro: Separately from these in vivo experiments, the expression of LPA receptors and the effects of LPA treatment on a variety of renal cell types were studied. It seems that, in vitro, LPA can induce biological effects on the majority of the kidney cell types: mesangial cells, renal tubular cells or renal fibroblasts.
-Mesangial cells (For review [44] ): Mesangial cells are an important cell type in the glomerulus, which is the filtration unit of the kidney. Mesangial cell activation (exemplified by mesangial profibrotic chemokine and cytokine secretion) and proliferation was identified in a number of renal pathologies [1] . LPA induces mesangial cell proliferation via mitogen-activated protein (MAP) kinase activation, contractility mediated by intra-cellular calcium mobilization, cyclic adenosine monophosphate (cAMP) accumulation, and prostaglandin E2 synthesis [45] [46] [47] . LPA can also be a mesangial cell survival factor, effects that are mediated by the Pi3k/Akt pathway [48] . Finally, LPA induces CTGF production by human mesangial cells [49] .
With this large variety of biological responses on mesangial cells, it is most likely that LPA is an important actor in glomerular pathologies.
-Proximal tubular cells: LPA induces tubular cell proliferation mediated by Pi3k/MAP kinase pathway activation and can inhibit serum starvation-induced apoptosis via the Pi3k/Akt pathway in primary culture of human tubular cells [45, 50] . LPA is also able to induce intra-cellular calcium mobilization in opossum kidney proximal tubule cells [51] . This increase might be the onset of NHE3 channel translocation and activation in apical membrane of tubular cells, consequently inducing Na++ absorption [52, 53] .
Finally, it was shown that primary culture human proximal tubular cells express the LPA 1 receptor [54] .
-Renal fibroblasts: LPA can induce CTGF expression and secretion, which is mediated by small GTPase Rho activation [29] .
LPA and renal fibrosis
Both -/-) ) and wild type mice (LPA 1 (+/+)) [19, 55] . Interestingly, the development of renal fibrosis was significant attenuated in LPA 1 (-/-) mice (Figure 2c ). This genetic invalidation was confirmed upon the use of the LPA 1 receptor antagonist Ki16425 [17, 18] . UUO mice treated with this antagonist closely resembled the LPA 1 (-/-) mice (Figure 2c ). These observations clearly demonstrated the crucial involvement of LPA and its receptor LPA 1 in the etiology of kidney fibrosis [31] . However, the contribution of the different renal cells in this profibrotic effect was less clear.
Since UUO-induced fibrosis is essentially interstitial, without visible glomerular lesions [56, 57] , the glomerular (mesangial cell) LPA 1 receptor is likely not involved in the effects of LPA on UUO-induced TIF. The other cell types that can be potential targets of LPA in the development of UUO-induced renal fibrosis include tubular-and inflammatory-cells and interstitial fibroblasts. Since it was already known that LPA can participate in intraperitonial accumulation of monocyte/macrophages [58, 59] and that LPA can induce expression of the pro-fibrotic cytokine CTGF in primary culture human fibroblasts [29] , we focused the remainder of our studies on the in vitro effects of LPA treatment on tubular cells. In addition, it has been shown that primary culture human proximal tubular cells express the LPA 1 receptor [54] . LPA treatment of a mouse epithelial renal cell line MCT [60] induced a rapid increase of the expression of profibrotic cytokine CTGF (Figure 2d ). CTGF plays a crucial role in UUO-induced TIF [61, 62] , and is involved in the pro-fibrotic activity of TGF [6] . This induction was almost completely suppressed by co-treatment with the LPA-receptor antagonist
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Ki16425 (Figure 2d ). Similar observations were previously made in renal fibroblasts and mesangial cells [25, 28, 29] , where the action of LPA on CTGF was shown to be mediated by the small GTPase rhoA and the down-stream kinase ROCK [28] .
Interestingly, treatments with ROCK-inhibitors have been described to attenuate UUO-induced renal TIF [63] , similar to what we observed in LPA 1 (-/-)-and in Ki16425-treated mice. Altogether, these observations strongly suggested that the pro-fibrotic activity of LPA in kidney could result from a direct action of LPA on kidney cells involving induction of CTGF (Figure 2, [31] ).
The metabolic origin of renal LPA remains to be determined. Several enzymes, including phospholipases A1/A2, lysophospholipase D/autotaxin (ATX), glycerolphosphate acyltransferase, or monoacylglycerol kinase (MAGK), can possibly lead to renal LPA synthesis [64] . The expression and/or the activity of one of these enzymes might be increased in the kidney as an adaptive response to chronic kidney injury induced by UUO. Preliminary data from our laboratory suggest that neither ATX nor MAGK are responsible for the increased synthesis of LPA associated with renal fibrosis, since their expression is rapidly and strongly down-regulated during UUO (data not shown). In rat, UUO was shown to increase the activity of a phosphoethanolamine-specific PLA2 [65] . The involvement of this enzyme in LPA synthesis in the obstructed kidney remains to be explored.
LPA receptor expression in other models of renal fibrosis
Although the UUO model of renal fibrosis mimics the different stages of the development of renal fibrosis, the rapidity by which these lesions are installed does not exactly correspond to the slow progression of human renal disease. The murine model of nephrotoxic serum (NTS) nephritis described by Lloyd CM et al [66] , is
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characterized by a rapid progressive glomerulonephritis followed by the slow appearance of TIF leading after several weeks to progressive renal failure [67] . This model more closely mimics the slow progression of human renal disease. We show here for the first time modification of LPA receptor expression in this chronic model (Figure 3) . As previously reported [67] , NTS-induced TIF is characterized by an increased expression of fibrosis markers (macrophage infiltration and collagen expression, Figure 3a) . Interestingly, renal expression of the LPA 1 receptor was significantly increased one and 6 weeks after NTS injection when compared to control mice (respectively 3,3 1 and 5,9 1,3 fold of control) (Figure 3b) . In contrast, the expression of the other LPA receptors was not modified. This suggest, as shown in the UUO model of accelerated renal fibrosis, that LPA and its receptors can play role in the development renal fibrosis originating from glomerulonephritis. An interesting aspect of this model is the fact that this disease is originating from glomerular inflammation. As we discussed above, LPA is inducing important biological effects on glomerular mesangial cells in vitro [45] [46] [47] [48] [49] . Therefore blockade of the effects of LPA in this model might modify the progression of disease in both the glomerular-and tubular-compartment. Further studies comparable to those performed with the UUO model [31] of renal fibrosis will be necessary to better understand the role of LPA and its receptors in CKD. all events known to be involved in the fibrotic process [7] . These results suggest that the LPA 1 receptor could become a promising new therapeutic target in fibrosis.
Conclusion
In the kidney, TGF seems to be only moderately involved in the anti-fibrotic effect of LPA 1 receptor blockade. This cytokine is one of the most potent pro-fibrotic factors involved in the (renal) fibrotic process. Since TGF has many other effects [68] , its blockage is not a realistic therapeutic option to reduce renal fibrosis. More recently, it has been proposed that CTGF blockade could represent a promising antifibrotic therapy [61] . Therefore, lowering CTGF production by pharmacological LPA 1 receptor blockade might be an interesting opportunity in the treatment of renal fibrosis. The development of fibrosis in CKD is comparable between the different renal compartments [1] . For clarity the development of only renal TIF is shown. The first step in the development of TIF is renal inflammation. This is leading to infiltration of macrophages, lymphocytes, and to increased cytokine and chemokine secretion. 
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